Program
TQB2916
A development code. Also written as “TQB2916 Injection”, “TQB2916 injection + doxorubicin hydrochloride for injection” and “TQB2916 injection+penpulimab injection”.
In Sino Biopharmaceutical's pipeline, CD40激动型单抗
. Its studies are mostly in Pancreatic Neoplasms · Sarcoma, led by Sino Biopharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 32 open or running | phase 2since Jul 8, 2024 | Jan 26, 2022 | Aug 2027phase 2 · NCT06962267 |
- Named in Sino Biopharmaceutical’s own pipeline as
TQB2916
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 26, 2022First study: phase 1 study in Advanced TumorsFirst studyNCT05213767 · 190 enrolled · China
- Jul 8, 2024Phase 2 study in SarcomaNCT06500091 · 54 planned · China
- Apr 30, 2025Phase 2 study in Pancreatic NeoplasmsNCT06962267 · 50 planned · China
Ahead
- Aug 2027Primary completion: phase 2 study in Pancreatic NeoplasmsNCT06962267
TargetBeta
“CD40激动型单抗”the company's pipeline, read by Claude · source
Other programs on CD40
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-MUC-1/Anti-CD40 Bispecific Antibody M0324rule | Merck KGaA, Darmstadt, Germany | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06962267Pancreatic Neoplasms · China | 2 | Recruiting | Aug 2027 | 50 |
| NCT06500091Sarcoma · China | 2 | Not yet recruiting | Jun 2026 | 54 |
| NCT05213767Advanced Tumors · China | 1 | UNKNOWN | May 2023 | 190 |
How it is read
Names in the registry
- “TQB2916 Injection”, 1 entry
- “TQB2916 injection + doxorubicin hydrochloride for injection”, 1 entry
- “TQB2916 injection+penpulimab injection”, 1 entry
- “TQB2916 injection”, 1 entry
Codes read as this program: TQB2916.
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 1 study
- Sarcoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.